Skip to main content
Premium Trial:

Request an Annual Quote

Yourgene Health Completes Acquisition of Elucigene Diagnostics

NEW YORK (GenomeWeb) – UK prenatal testing firm Yourgene Health said late last week that it has completed the acquisition of Delta Diagnostics, which trades under the name Elucigene Diagnostics.

Yourgene had said earlier this month that it was planning to acquire Elucigene for £9.2 million ($12 million) in cash and stock. Both companies are located in Manchester, UK.

Elucigene has been developing in vitro diagnostics for oncology and reproductive health, including tests for cystic fibrosis screening and prenatal fetal aneuploidy screening.

Yourgene said that Elucigene's product portfolio is complementary to its own. Following the acquisition, it plans to develop and launch additional next-generation sequencing and other molecular diagnostic products.

"The commercial, scientific, and financial opportunities created by the acquisition are hugely exciting and we look forward to combining our respective Manchester operations," said Yourgene CEO Lyn Rees in a statement.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.